Date

March 18

Venue

digital: Teams

Time

08:30 - 09:45

INVITATION – Strategic Routes for Entering the Chinese Life Science Market

How do you go about entering the Chinese life science market? What options are appropriate for China market entry? What are the tips and tricks to consider?

The China healthcare industry is ranked the second largest in the world behind the US, and is growing at a consistently rapid rate. The third webinar in Swecare's series focusing on the Chinese healthcare market will give discuss various options for market entry, and offer first-hand insights from two Swedish companies that recently have ventured into the market. 
 

In the webinar representatives of Nordic Match, financial advisors dedicated to Sino-Nordic transactions will cover various strategies for entering the Chinese life science and healthcare market, such as partnerships, JV, inbound M&A, direct investments and licensing

After presenting important implications of these strategic choices, two companies that recently have entered the the Chinese market share their experiences, tips and tricks. We will also have time for questions and discussions regarding Chinese market entry. 

In short, this webinar will give you valuable information on requirements for doing business in the Chinese life sience and healthcare market, and we hope that you will join us. 

Agenda:
08:30 – 08:35 Welcome and Introduction
Anna Riby – Swecare
 
08:35 – 09:05 What are the different strategic routes to consider when entering China?
Markus Dahlström, Partner, and Tony Wang, Partner, Nordic Match

09:05 - 09:15 Story-sharing from Calmark's China journey
Anna Söderlund, CEO, Calmark
 
09:15 – 09:25 Story-sharing from Vironova's China journey
Mohammed Homman, CEO, Vironova

09:25 – 09:45 Q&A, discussion and summary

 

Information and registration
For more information: send an e-mail to info[@]swecare.se
Date: 18 March
Time: 08:30-09:45
Venue: webinar - Teams platform
Language: Swedish or English depending on participants
Cost: Free
Registration deadline: March 12